Our track record and strength in medicinal chemistry is a key competitive advantage, enabling us to develop novel, efficacious therapeutics that function through the regulation of gene expression for the treatment of chronic disease.

Stephen Shuttleworth PhD FRSC, Chief Scientific Officer